NMTR
Price:
$0.0722
Market Cap:
$1.04M
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prev...[Read more]
Industry
Biotechnology
IPO Date
2016-07-11
Stock Exchange
NASDAQ
Ticker
NMTR
According to 9 Meters Biopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -1215.30%. This represents a change of 1.06% compared to the average of -104.58% of the last 4 quarters.
The mean historical ROE of 9 Meters Biopharma, Inc. over the last ten years is -5.98%. The current -1215.30% ROE has changed 20.21% with respect to the historical average. Over the past ten years (40 quarters), NMTR's ROE was at its highest in in the June 2017 quarter at 769.01%. The ROE was at its lowest in in the June 2020 quarter at -1453.97%.
Average
-5.98%
Median
187.59%
Minimum
-1896.06%
Maximum
660.34%
Discovering the peaks and valleys of 9 Meters Biopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.04%
Maximum Annual ROE = 660.34%
Minimum Annual Increase = -262.67%
Minimum Annual ROE = -1896.06%
Year | ROE | Change |
---|---|---|
2022 | -1896.06% | 2.04% |
2021 | -88.52% | -56.59% |
2020 | -203.92% | -167.90% |
2019 | 300.33% | -54.52% |
2018 | 660.34% | 64.40% |
2017 | 401.67% | -260.85% |
2016 | -249.72% | -262.67% |
2015 | 153.51% | -30.75% |
2014 | 221.67% | -65.41% |
The current ROE of 9 Meters Biopharma, Inc. (NMTR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-729.50%
5-year avg
-245.56%
10-year avg
-5.98%
9 Meters Biopharma, Inc.’s ROE is greater than Mereo BioPharma Group plc (-63.39%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Inozyme Pharma, Inc. (-68.93%), less than Galera Therapeutics, Inc. (21.95%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than Artelo Biosciences, Inc. (-37.69%), greater than Histogen Inc. (-108.33%), greater than Curis, Inc. (-328.39%), greater than Timber Pharmaceuticals, Inc. (-520.78%), less than Kineta, Inc. (934.78%), greater than Candel Therapeutics, Inc. (-629.29%), less than MiNK Therapeutics, Inc. (99.78%), greater than Forte Biosciences, Inc. (-117.85%), greater than AlloVir, Inc. (-96.48%), less than ZIVO Bioscience, Inc. (673.84%), greater than RenovoRx, Inc. (-403.38%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than Ikena Oncology, Inc. (-42.81%), less than Catalyst Biosciences, Inc. (1.20%), less than MEI Pharma, Inc. (48.32%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than Vincerx Pharma, Inc. (-276.65%), greater than Avenue Therapeutics, Inc. (-749.10%),
Company | ROE | Market cap |
---|---|---|
-63.39% | $664.26M | |
-24.63% | $133.38M | |
-122.70% | $1.25B | |
-68.93% | $312.42M | |
21.95% | $4.08M | |
-47.94% | $60.66M | |
-37.69% | $3.87M | |
-108.33% | $939.79K | |
-328.39% | $29.78M | |
-520.78% | $1.18M | |
934.78% | $8.08M | |
-629.29% | $197.00M | |
99.78% | $31.17M | |
-117.85% | $11.11M | |
-96.48% | $88.16M | |
673.84% | $37.03M | |
-403.38% | $24.47M | |
-201.10% | $31.26M | |
-42.81% | $81.56M | |
1.20% | $19.42M | |
48.32% | $20.65M | |
-61.71% | $42.44M | |
-54.50% | $40.82M | |
-276.65% | $22.05M | |
-749.10% | $4.05M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 9 Meters Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 9 Meters Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is 9 Meters Biopharma, Inc.'s ROE?
How is the ROE calculated for 9 Meters Biopharma, Inc. (NMTR)?
What is the highest ROE for 9 Meters Biopharma, Inc. (NMTR)?
What is the 3-year average ROE for 9 Meters Biopharma, Inc. (NMTR)?
What is the 5-year average ROE for 9 Meters Biopharma, Inc. (NMTR)?
How does the current ROE for 9 Meters Biopharma, Inc. (NMTR) compare to its historical average?